Dalriada Wordmark

Small Molecule Discovery Meetings 2023

Meeting List

Meeting Details

Conference: Biotech Showcase


The Biotech Showcase is an annual conference that brings together investors, analysts, biotech executives, and other industry leaders to discuss the latest developments and trends in the biotech industry. The conference typically features presentations from hundreds of private and public companies in the biotech sector, as well as panel discussions and networking opportunities.

The Biotech Showcase is generally considered one of the premier events in the biotech industry, and is known for attracting a high-caliber group of attendees from around the world. Topics that are typically covered at the conference include drug development, clinical trials, regulatory issues, and financing strategies for biotech companies.

The Biotech Showcase is usually held in January each year in San Francisco, in conjunction with the J.P. Morgan Healthcare Conference, which is another major event in the biotech and healthcare industries.

Official Website: https://informaconnect.com/biotech-showcase/

Dalriada team attended this event.

Location:  San Francisco, USA

Date:  January 9, 2023

Conference: BioSeed


BioSeed, which is organised byOBN​is a fast-paced, one-day pitching event where innovative early-stage Life Sciences companies seeking Seed funding, showcase to and meet with an extensive audience of active life sciences investors.

Key features of the event include:

  • 40 x 5-minute company presentations from early-stage life sciences R&D companies seeking seed stage funding
  • Inspirational keynote presentations and an investor workshop
  • Private pre-scheduled partnering meetings in-person on 23 January, and virtually on 24 January (powered by PartneringONE)
  • Plenty of networking opportunities throughout the day, along with a Networking Drinks Reception at the end of day one


Official Website: https://obn.glueup.com/event/bioseed-2023-monday-23-january-london-53739/

Dalriada team attended this event.

Location:  London, UK

Date:  January 23, 2023

Conference: 16th Winter Conference on Medicinal & Bioorganic Chemistry


The Medicinal & Bioorganic Chemistry Foundation (MBCF) held the 16th Winter Conference on Medicinal & Bioorganic Chemistry (16th WCMBC)  January 29th – February 2nd 2023 at the beautiful Steamboat Springs Resort, Colorado.

Program topics included:

  • Drug Hunting
  • Enabling Methodology and Technology
  • Antivirals and Pandemic Diseases, Past, Present and Future
  • SynthChemBio
  • Beyond Ro5 and Novel Modalities
  • MacMillan Alumni Session: Topics in Medicinal and Synthetic Chemistry
  • Late Breaking Stories and 1st Disclosures
  • General Session


Official Website: https://mbcfconference.com/events/16th-winter-conference/

Location:  Steamboat Springs CO, USA

Date:  January 29, 2023

Conference: 2nd GPCR-Targeted Drug Discovery Summit


Returning for the 2nd year, the GPCR-Targeted Drug Discovery Summit is the only industry-led meeting of its kind dedicated to congregating the most forward thinking biotechs, established large pharma, and key academic opinion leaders committed to discovering and validating the next wave of GPCR targets across a breadth of indications.

Official Website: https://gpcrs-drugdiscovery.com/

Dalriada team attended this event.

Location:  Boston, USA

Date:  February 21, 2023

Conference: Precision Medicine Conference


The conference is intended to have interactive sessions on precision medicine, application of pharmacogenomics, complex diseases prediction and treatment, technological advancements in diagnosis of diseases, artificial intelligence and bigdata, challenges and ethical considerations in precision medicine.

The event encompasses networking sessions, panel discussions, solutions, and services catering to precision medicine. The conference will bring the full spectrum of experts, leaders, and stakeholders to share a board prospective on opportunities and overcoming the challenges faced during implementation of precision medicine in clinical practice.

Official Website: https://events.marketsandmarkets.com/precision-medicine-conference/

Location:  London, UK

Date:  March 9, 2023

Conference: Protein Degradation & Targeting Undruggables Congress


The Protein Degradation & Targeting Undruggables Congress is a conference focused on the latest advancements in the field of targeted protein degradation and drug discovery.

The event brings together experts from academia, industry, and government to discuss new approaches and innovative strategies for tackling traditionally “undruggable” targets. Attendees will have the opportunity to learn about the latest developments in the field, explore new therapeutic strategies, and network with key opinion leaders and professionals who are shaping the future of drug development.

Topics covered may include the use of small molecules, peptides, and other modalities to target proteins for degradation, the development of novel drug delivery methods, and the application of cutting-edge technologies such as CRISPR/Cas9 gene editing.

Patrick Gunning, our Co-Founder & CSO, will also speak at the event. Check out Patrick’s bio here.

Official Website: https://www.kisacoresearch.com/events/PDTU-2023#

Dalriada team attended this event.

Location:  Boston, USA

Date:  March 15, 2023

Conference: BIO-Europe Spring


Expanding on the success of EBD Group’s flagship conference, BIO-Europe® , BIO-Europe Spring will bring together over 2,800 leading executives from around the world. Specifically, we will host more than 15,000 partnering meetings to connect leaders from academia, start-up, and scale-up biotech companies with forward-thinking investors and pharma companies. Along with world-class workshops and panels, innovative company presentations, active exhibition and a variety of networking opportunities make this event an unrivalled forum for companies across the biotech value chain to meet and do business.

Official Website: https://informaconnect.com/bioeurope-spring/

Dalriada team attended this event.

Location:  Basel, Switzerland

Date:  March 20, 2023

Conference: Frontiers in Medicinal Chemistry


The international symposium will focus on current developments, novel approaches and cutting-edge technologies in the field of medicinal chemistry and drug research with sessions on

  • First Disclosures & Medicinal Chemistry Highlights
  • Molecular Glues & Degraders
  • RNA-Modifying Enzymes
  • Translational Science Case Studies
  • New Chemical Technologies
  • In Silico Solutions in MedChem
  • Young Investigators.


The scientific program will include lectures, and poster presentations. It is the goal of the organizers to make this meeting an event of scientific excellence, attractive to both industrial and academic scientists in Medicinal Chemistry, Chemical Biology, and related fields of research.

Official Website: https://veranstaltungen.gdch.de/tms/frontend/index.cfm?l=11444&sp_id=2

Location:  Vienna, Austria

Date:  April 3, 2023

Conference: Drug Discovery Chemistry


Drug Discovery Chemistry is a dynamic conference for medicinal and biophysical chemists working in pharma, biotech, and academia. Focused on discovery and optimization challenges of small molecule drug candidates, this event provides many exciting opportunities for scientists to create a unique program to hear presentations most suited to one’s personal interests by going back and forth among concurrent tracks. New for 2023 is coverage of targeting transcription factors, plus greatly expanded coverage of protein degraders, molecular glues, and artificial intelligence for early drug discovery.

Official Website: https://www.drugdiscoverychemistry.com/

Location:  San Diego, USA

Date:  April 10, 2023

Conference: AACR Annual Meeting 2023


The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer biology, translational, and clinical studies; to survivorship and advocacy; the AACR Annual Meeting highlights the work of the best minds in cancer research from institutions all over the world.

Official Website:  https://www.aacr.org/meeting/aacr-annual-meeting-2023/

Location:  Orlando, FL, USA

Date:  April 14, 2023

Conference: Swiss Biotech Day 2023


The Swiss Biotech Day has become one of the leading biotechnology conferences in Europe and a fixed date in the community’s calendar. In 2022, the conference highlighted the impressive growth of the Swiss biotech industry and presented an exciting program with ideal networking opportunities for over 1,100 participants from across the globe.

In 2023, the Swiss Biotech Day will again offer high-level experts from the life sciences industry the space and the time (one and a half days) to network, discuss and discover trends in R&D, manufacturing, data management, artificial intelligence and innovative financing. In addition, international biotech delegations can visit the “Global Village” to strengthen their ties with Switzerland as a biotech hub and promote cross-border investments, public-private partnerships, research and development collaborations and exchange of talent. 

What to expect:

  • Meet over 1,000 senior experts from the life science industry
  • More than 70 exhibitors and Global Village with international delegations from all over the world
  • Swiss Biotech Success Stories awards
  • Innovative biotech start-ups and medium-sized biotech companies
  • Thematically-focused panel discussions
  • Swiss Biotech Report 2023
  • Pre-scheduled one-to-one partnering meetings
  • General assembly of the Swiss Biotech Association
  • One-to-one partnering


Official Website: https://swissbiotechday.ch/

Location:  Basel, Switzerland

Date:  April 24, 2023

Conference: BioTrinity 2023


BioTrinity is an established, must-attend London conference, that catalyses growth and supports in-person engagement across the life sciences industry.

The event is attended by an audience of early stage and emerging life sciences R&D Companies, investors, big pharma, and other valued partners throughout the life sciences ecosystem. The conference features a focused, relevant, and stimulating programme, led by great speakers, who bring their knowledge, expertise, and vision to the fore in exciting, high-quality sessions.

Interacting with new companies each year is something we believe to be a critical attribute of a successful conference and we work hard to ensure that a substantial and fresh line-up of investable opportunities and collaboration possibilities are showcased.

BioTrinity features:

  • A dedicated ‘Scientific Track’, featuring a focus on eight core therapy areas; Oncology, Neuroscience, Microbiome, Inflammatory Diseases, Rare Diseases, Infectious Diseases, Medtech and Cell & Gene Therapy. Each dedicated session will include an expert update from a key opinion leader, followed by up to 5 showcase presentations from some of the most innovative and interesting R&D companies.
  • A second ‘life sciences business’ focused presentation track, that will feature discussions and keynotes addressing topics from finance and investment, regulatory, government strategy and tax.
  • Pre-scheduled live & in-person private partnering meetings during the two-day physical conference as well as a bonus third day of virtual only partnering.
  • A sponsors exhibition area and plenty of ‘all-delegate’ networking opportunities throughout both in-person day, which are so valuable to share knowledge and unlock future collaboration and new business opportunities.
  • Option for registered delegates to revisit recorded presentations in the days following the conference.


Official Website: https://obn.glueup.com/event/biotrinity-2023-57830/

Location:  London, UK

Date:  April 25, 2023

Conference: 34th Medicinal Chemistry in Eastern England


Known colloquially as the “Hatfield MedChem” meeting, this is a highly successful, long-standing, one-day meeting that runs annually. The scientific program will comprise presentations showcasing medicinal chemistry case studies from tools to candidates, across a range of modalities, therapeutic areas and target classes, as well as covering more general topics at the forefront of drug discovery. The meeting aims to be informal and interactive, and is ideal for all those working in medicinal chemistry and drug discovery more widely.

Official Website: https://www.rscbmcs.org/events/mcee-2/

Location:  London, UK

Date:  April 27, 2023

Conference: LSX World Congress 2023


The 9th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core.

The event brings together the CEOs and senior decision makers from the world’s most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs. Together, they share best practice, forge partnerships and investments – all geared at putting capital and ideas to work to help create the world’s future medicines and improve patient outcomes.

From therapeutics to techbio, devices to digital health, deep tech to platform tech and diagnostics to delivery tools, it represents the breadth, depth and convergence of the cutting-edge research and technology driving advances in the healthcare industry right now, and in the future.

Official Website: https://www.lsxleaders.com/lsx-world-congress

Location:  London, UK

Date:  May 3, 2023

Conference: 8th Edition Meet2Win: European Oncology Partnering Convention


The MEET2WIN convention brings together every year nearly 300 European players specifically involved in translational research and innovation in oncology in the broad sense (researchers, clinicians, entrepreneurs, biotechs, pharmaceutical groups, investors, support structures, etc.) wiling to expand their network of contacts and optimize their collaboration around the fight against cancer.

For this 8th edition, this European-scale event will offer over 2 days:

  • round tables presenting the latest innovations in oncology with opinion leaders and institutional representatives;
  • forums for presenting innovative projects (academic teams or young companies);
  • a session proposing financing solutions to support the development of projects;
  • thematic workshops offered by organizations involved in the innovation chain (service companies, biotechs, pharmaceutical laboratories, etc.);
  • a job dating session to facilitate the connection between companies looking for skills and talents looking for a job;
  • a space entirely dedicated to networking and meetings between actors (+ than 1000 face-to-face meetings organized during the 2 days)

Official Website: https://matwin.fr/en/meet2win-2022/

Location:  Bordeaux, France

Date:  May 11, 2023

Conference: 23rd Bioequity Europe


Bio€quity Europe is the industry’s premier CEO and investor conference.

At Bio€quity Europe, you will:     

  • Debate new strategies for biotech success in Europe over two days of discussion designed for the C-Suite. 
  • Meet one-to-one with top VCs and biopharma decision-makers looking for deals.
  • Network with investors, CEOs, CFOs, and BD heads from across the innovation ecosystem.
  • Hear from 120+ rising biotechs selected to present by BioCentury.
  • Understand key industry trends in a conference report from Insights Partner, McKinsey & Company
  • Use BioCentury’s business intelligence platform (pipelines, financings, deals, analysis) to prepare for your partnering meetings.


Official Website: https://conferences.biocentury.com/bioequity-europe

Location:  Dublin, Ireland

Date:  May 14, 2023

Conference: 6th Meridian Drug Discovery


Meridian Drug Discovery is a bi-annual event series hosted by Continuum Globe Ltd. A venue for exchanging scientific knowledge and a business incubator for vendor and sponsor engagements. Networking, knowledge exchange, and partner outreach are all made more accessible by MDD.

Official Website: https://meridiandrugdiscovery.com/

Location:  New York, USA

Date:  May 18, 2023

Conference: Bio International Convention


The BIO International Convention attracts 14,000+ biotechnology and pharma leaders for one week of intensive networking to discover new opportunities and promising partnerships.

Innovative programming around the current and future state of biotech. Including areas like therapeutic frontiers, the business of biotech, regulatory and policy outlooks, and human capital.

Official Website: https://www.bio.org/events/bio-international-convention

Dalriada team attended this event.

Location:  Boston, USA

Date:  June 5, 2023

Conference: Discovery Europe 2023


Exploring the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit.

The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimisation.

The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.

Official Website: https://www.oxfordglobal.co.uk/discovery-series/

Location:  Berlin, Germany

Date:  June 6, 2023

Conference: Neuroscience Drug Development Europe 2023


This in-depth 2 day event will detail the journey of neuroscience discovery from initial lead through to clinical trials, bringing together leading companies for discussion, knowledge-sharing and focused networking.

Track 1: Therapeutic Strategies, Enabling Technologies & Biomarker Development 

  • Advancements and emerging trends in the application of technology in developing neurological treatments 
  • Neuroscience biomarker development 
  • Translational approaches for drug discovery 
  • Opportunities and challenges of designing and implementing targeted diagnostics and therapeutics 
  • Diagnostic tool development


Track 2: Drug Discovery for Neurodegenerative Diseases 

  • Target identification and validation approaches 
  • Stem cell technology to fuel drug discovery 
  • iPS cells for disease modelling and drug discovery 
  • Blood brain barrier in CNS drug discovery 
  • Assay Development & Screening 
  • In vitro and in vivo disease modelling 
  • The role of informatics in CNS drug discovery 


Official Website: https://www.oxfordglobal.co.uk/neuroscience/

Location:  Berlin, Germany

Date:  June 6, 2023

Conference: European Mediscience Awards


Showcasing achievement and success in the UK and European healthcare, biotech, pharmaceutical and life sciences sectors
The European Mediscience Awards is now in its 21st year, having been held every year since inception in 2002*. The event is the largest annual gathering of private and publicly quoted healthcare, biotech and life sciences companies in Europe. Bringing together the best of European mediscience companies to celebrate achievement and recognise success, it is the must-attend event for anybody working in this sector.

Each year sees the attendance of over 500 quoted and private UK and European life sciences companies and their corporate advisers, analysts, fund managers, commentators and peers. The event is sold out from one year to the next.

The European Mediscience Awards 2023 will take place on Thursday 15 June at the Hotel InterContinental, London, W1.

Official Website:  https://www.mediscience-event.co.uk/

Location:  London, UK

Date:  June 15, 2023

Conference: SCI / RSC 22nd Medicinal Chemistry Symposium


The organisers invite you to the 22nd SCI-RSC Medicinal Chemistry symposium, Europe’s premier biennial Medicinal Chemistry event, focusing on first disclosures and new strategies in Medicinal Chemistry.

Official Website: https://www.soci.org/events/fine-chemicals-group/2023/sci–rsc-22nd-medicinal-chemistry-symposium

Dalriada team attended this event.

Location:  Cambridge, UK

Date:  September 10, 2023

Conference: ELRIG Drug Discovery


Europe’s largest meeting for life sciences industry professionals. During this conference, ELRIG will celebrate its long history of hosting disruptive and innovative drug discovery technology developments, whilst exploring the next life science revolutions

Official Website: https://www.elrig.org/portfolio/drug-discovery-2023/

Location:  Liverpool, UK

Date:  October 18, 2023

Conference: Society For Neuroscience 2023


Neuroscience 2023 will be held at the Walter E. Washington Convention Center in Washington, D.C., November 11-15, 2023.

Each year, scientists from around the world congregate to discover new ideas, share their research, and experience the best the field has to offer. Attend so you can: present research, network with scientists, attend session and events, and browse the exhibit hall.

Join the nearly half a million neuroscientists from around the world who have propelled their careers by presenting an abstract at an SfN annual meeting — the premier global neuroscience event. 

Official Website: https://www.sfn.org/meetings/neuroscience-2023

Location:  Washington, USA

Date:  November 11, 2023

Conference: European Lifestars Awards


The European Lifestars Awards are instrumental in highlighting the incredible work being carried out across the life science value chain.

Official Website: https://www.lsxleaders.com/lifestars-awards

Location:  London, UK

Date:  November 13, 2023

Conference: OBN Awards


The OBN Awards are a highly regarded and sought-after awards programme for the Life Sciences industry, designed to celebrate innovation and outstanding achievement across all corners of the life sciences industry.

Location:  London, UK

Date:  November 15, 2023

Conference: Scrip Awards 2023


The Scrip Awards brings together over 400 industry leaders to celebrate and recognise the very best innovations and achievements in global biopharma. Winners will be celebrated across 15 categories, covering a full spectrum of advancements, from Best New Drug, Community Partnership of the Year, Clinical Advance of the Year and Best Contract Research Organisation.

Dalriada team is looking forward to attending this event.

Location:  London, UK

Date:  November 16, 2023

Conference: Nordic Life Science Days 2023


For the first time since its inception in 2013, the Nordic Life Science Days will take place in Copenhagen-Denmark at Bella Arena-Bella Center on 29-30 November.

This will be a unique opportunity to partner and network with the best of Nordic and International leaders in life sciences and celebrate together our 10th anniversary.

Official Website: https://www.nlsdays.com/

Location:  Copenhagen, Denmark

Date:  November 29, 2023

Conference: Discovery US 2023


Exploring the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit.

The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimisation.

The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling.

Location:  Boston, USA

Date:  November, 2023


Taleb Sedighi, PhD

Director of Proteomics and Protein MS

Taleb is a distinguished scholar with a PhD in Bioanalytical Chemistry from Simon Fraser University in Canada, complemented by an MSc and BSc in Analytical Chemistry. With a robust 16 years of experience, Taleb’s expertise lies in utilizing mass spectrometry techniques for the analysis of proteins and small molecules.

Since joining Dalriada in January 2021, Taleb has led the development of innovative platforms in chemoproteomics and covalent hit identification cascade, which have significantly contributed to over 20 covalent and targeted protein degradation programs.

Before joining Dalriada, Taleb was a Research Associate at the Patrick Gunning lab at the University of Toronto, where he played a pivotal role in establishing various proteomics and DMPK methods crucial for supporting early drug discovery programs.

Beyond his professional accomplishments, Taleb’s passion for science and research is evident, underscored by his authorship of 46 publications and numerous contributions to patent filings and grant proposals.

Pegah Ghiabi, PhD

Associate Director, Protein Production

Pegah brings over 25 years of extensive experience in biomedical research and leadership, Pegah brings a wealth of expertise in cancer research, protein science, and drug discovery within academic settings.

Prior to joining Dalriada, Pegah served as a senior research associate and Head of the protein production core facility at the Structural Genomics Consortium (SGC), University of Toronto. In this role, she provided strategic guidance and supervision for generating protein targets crucial to numerous drug discovery projects, collaborating with both academic and industry partners. Notable collaborations included projects with Nurix Therapeutics, Pfizer, Bristol Myers Squibb, Takeda, Merck KGaA, Janssen, Novartis, and X-Chem.

As a leader of the protein production team, Pegah brings unparalleled expertise in human and viral protein production. Her proficiencies span target selection, construct design, expression vector selection, protein expression across bacterial, insect, and mammalian systems, protein purification, and biophysical approaches for protein quality assessment. Pegah boasts extensive experience across various target classes, including helicases, proteases, methyltransferases, exonucleases, E3 ligases, polymerases, the WDR protein family, and structural proteins in both human and viruses.

Pegah holds an MSc in Cell Biology from McGill University, Canada, and a PhD in Cellular and Molecular Biology from the University of Paris-Sud (XI), France. After her doctoral studies, she undertook a postdoctoral position at Weill Cornell University in the USA.

Chris Yarnold, PhD

Director, Discovery Chemistry

Chris brings over 20 years’ industrial integrated discovery, medicinal chemistry and project leadership experience.

Prior to joining Dalriada, Chris spent 20+ years at Evotec (UK) as Group Leader in Medicinal/Discovery Chemistry where he was Project Leader for drug discovery projects covering a broad range of Therapeutic Areas and was Global Medicinal Chemistry contact for Metabolic Diseases.

Chris has experience as Project Leader in major disease areas including Cardiovascular, Oncology, CNS and Metabolic diseases.  Additionally, Chris has led anti-infective, iron overload disease and anti-thrombotic collaborations. His expertise includes hit finding and expansion, Hit-to-Lead and Lead Optimization preclinical phases. Three clinical candidates were identified. FV-100 has reached PhIII for shingles, Vamifeport is progressing through PhIIa for iron overload diseases and ONO-7684 is currently in PhI trials as a novel antithrombotic agent.  He has experience in targeting enzymes, GPCRs and transporters with small molecules. Chris has extensive experience of managing teams, encouraging and developing chemists to reach their full potential.

Chris has a B.Sc (Joint Hons) in Chemistry and Biology and a Ph.D. from King’s College London. Chris gained postdoctoral experience with Professor Walter Szarek at Queen’s University, Kingston, Canada and Professor Chris McGuigan at the Welsh School of Pharmacy, Cardiff.

Kaushik Ghosal, PhD

Head of BD, North America

Kaushik Ghosal is a successful entrepreneur and business development executive with over 15 years of bio-pharma experience in a variety of R&D and BD roles across several verticals in R&D business models, corporate expansion and strategic leadership in drug discovery and early development. Most recently Kaushik was Director of BD at Evotec (NASDAQ: EVO) leading partnered drug discovery and development programs for both stand alone and integrated drug discovery projects for several small and large biotechs, drug development accelerators and large pharma clients. 

​Prior to Evotec, Kaushik was the Director of Business Development at BioMotiv where he was instrumental in launching and leading a portfolio of venture-backed biotechs such as Sujana Bio, Optikira, Koutif Therapeutics. During his tenure, BioMotiv and Harrington project grew into a 360M + global initiative and established strategic partnerships with Takeda, Biogen, Arix Bioscience and Charles River Laboratories. At BioMotiv, Kaushik also founded therapeutic focused start-ups such as BioExcel and Inclera therapeutics to advance academic sourced drug discovery programs, some of which developed into clinical stage assets.

Before BioMotiv, Kaushik was Director of R&D at ReXceptor Inc, a clinical stage biotech company where he led preclinical and clinical development, establishing strategic partnerships with pharmaceutical companies and drug-development accelerators. 

Kaushik received MSc in Biotechnology (Indian Institute of Technology, Bombay), a Ph.D. from Miami University and completed his postdoctoral training in Neuroscience from the Cleveland Clinic. Kaushik has served on various advisory and on the boards of non-profit and for-profit organizations in the healthcare field such as NIH, John Hopkins Technology Ventures, EDI and Case Venture Mentorship Program.

Richard Rathmell, PhD

SVP Discovery Chemistry

Rich is Dalriada’s SVP Discovery Chemistry, responsible for scientific strategy of programs in discovery chemistry and a key contributor to the continuous R&D capability build at Dalriada. He brings 23 years of discovery experience, medicinal chemistry, and project leadership working at Eli Lilly and most recently Evotec, in the UK.  

Before joining Dalriada, Rich was Vice President and Head of a Chemistry Department at Evotec UK, where he held strategic and scientific direction oversight for a portfolio of pain and metabolic disorder programs. He helped to shape the vison and direction of the chemistry group and additionally was a key contributor developing new screening strategies, and designing associated libraries, for early phase projects.

Prior to Evotec, Rich gained exceptional experience in integrated drug discovery with a 20+ year career at Eli Lilly UK. He held the positions of Group Leader and Research Advisor, where he had oversight for the portfolio management of his team. Scientifically, Rich has been involved in 25+ integrated drug discovery programs across neurosciences, pain, and metabolic disorders. His expertise spans all stages of drug discovery, from target identification and validation to Hit-to-Lead and Lead Optimization, culminating in the delivery of 8 clinical candidates, two reaching PhI and one still progressing through PhIIa for Alzheimer’s disease. He is familiar with multiple modalities, from small molecules, protein-protein interactions, protein degradation, protein translation inhibition and peptides. He brings extensive experience with target classes such as GPCRs, enzymes, transporters, and ion channels.

Rich has a B.Sc (Hons) and a Ph.D in Chemistry from the University of Exeter UK, before taking up a postdoctoral position working with the late Sir Jack Baldwin at the University of Oxford.

Adam Davenport

Adam Davenport, PhD

Chief R&D Officer

Adam is Dalriada’s Chief R&D Officer. A seasoned drug hunter and innovator, he brings over 22 years of hands-on life science and partnership organization experience, having contributed to drug candidates and clinical assets through both governance and leadership roles.

Prior to Dalriada, Adam’s outstanding career was spent at Evotec, then Oxford Asymmetry International, which he joined in 2001. There, he gained extensive experience from Hit ID through to IND, across diverse modalities, target classes (GPCRs, ion-channels, PPIs, CNS, kinases, enzymes) and therapeutic areas (pain, inflammation, cognition, metabolic, Women’s Health and respiratory).

As a Project Leader, Adam has progressed multiple projects through Discovery into Clinical evaluation and is lead inventor of P2X3R antagonists Eliapixant and Filopixant, achieving Phase 2a PoCs in Persistent Chronic Cough (PCC), and Bradykinin B1R antagonist Fulimetibant, undergoing a Phase 2a study to treat diabetic neuropathic pain (DNP).

Adam’s promotion to VP Medicinal Chemistry saw him take on scientific and strategic portfolio responsibilities as well as operational duties in Abingdon, UK. Progression through Senior to Executive VP expanded Adam’s leadership and strategic influence on the organisation, where he established and led as Head of Global Molecular Discovery, a multi-modality data-driven Design and Synthesis function based in the UK, FR, IT and US.

Passionate about science and communication, Adam has authored over 55 patents, publications and external presentations and was co-recipient of the Bayer Healthcare Drug Discovery Award for Collaborative Innovation in 2017.

Adam holds a B.Sc. Honours degree in Chemistry and a PhD in Organometallic Chemistry from the University of Leicester, UK.

Frosty Loechel, PhD

SVP Biology

Frosty is Dalriada’s Head of Biology, responsible for the scientific strategy of the discovery program in biology and a key contributor to the continuous evaluation of our scientific capabilities, operations, and infrastructure. He brings 20 years’ academic experience and 25 years working in pharma, biotech, and CROs.

Before joining Dalriada, Frosty gained exceptional experience in discovery programs at Evotec. First as a VP, Metabolic diseases, he built up a large department running iPSC work, in vitro pharmacology, advanced cellular platforms, transcriptomics, imaging, and data science. Then, as SVP, Therapeutic Area Lead and Scientific Director, he led on new collaborative drug discovery agreements with pharma/biotech partners and on the strategy of project portfolio in major multi-target collaborations.

Prior experience includes work at Zealand Pharma, where he focused on peptide drugs for a portfolio of diabetes and obesity projects. His earlier career was spent at Lundbeck, Thermo Fisher, Neurosearch and BioImage, where he gained a strong background in a broad spectrum of scientific areas.

Frosty has been involved in hundreds of drug discovery projects and gained a wealth of experience across multiple areas and therapeutic modalities including CNS and metabolic diseases. His expertise spans all stages of drug discovery, from target identification and validation to Hit-to-Lead and Lead Optimization, and nomination of preclinical candidates. He is familiar with multiple modalities, from small molecules, to peptides, to biologics, and brings extensive experience with target classes such as GPCRs, kinases, transporters, ion channels and proteases.

Frosty has a B.A. in Biochemistry from the University of Kansas, and a Ph.D. from the Faculty of Health Sciences of the University of Copenhagen. He is a Danish citizen and is fluent in English, Danish, and Italian.

Come Work With Us

Help discover small molecule therapies that could change the world​

Brian Sequeira

Brian Sequeira

Director, Information Systems, PMO

As Director of Information Systems and PMO, Brian leads the IT, PMO and Procurement functions. With a strong foundation in technology, a successful track record in leading cross functional and multi-disciplinary project management teams, and in-depth experience in purchasing and materials management, Brian is passionate about delivering to and exceeding client expectations through critical thinking, analysis and effective communication. He brings more than 20 years experience in various industries including corporate law, pharmaceuticals, biopharmaceuticals and big data market research.

Brian completed his BSc degree in Computer Science from the University of Toronto and certified as a Project Management trainer with Kepner Tregoe.

Lisa Cline

Lisa Cline

Director, Human Resources​

As the Director of Human Resources (HR), Lisa leads this function at Dalriada. Lisa is recognized as a pragmatic partner, team builder and innovator who brings balance and clarity to HR policies, practices, and procedures.

With more than 25 years in a management capacity, Lisa is known for designing and developing programs, performance improvement measures and policies that help organizations build highly engaged workplaces, boost their bottom line, and defuse workplace issues before they escalate.

She began her HR career at GlaxoSmithKline advancing through increasingly responsible positions and supporting practically every division within the company. Lisa has also operated her own HR consultancy. Since joining Dalriada in 2020, Lisa has established an efficient and engaging HR infrastructure that delivers sustainable organizational and cultural success.

Lisa attained her Certified Human Resources Leader designation, (CHRL) from the University of Toronto.

Harpreet Kaur

Harpreet Kaur, PhD

Director Chemistry & ADME

As Director of R&D Operations, Harpreet leads Dalriada’s Chemistry and ADME functions. Passionate about building highly effective, result-oriented teams, Harpreet is known for her strong rapport with clients and inter-disciplinary colleagues.

Harpreet brings more than 20 years R&D experience in both academic and industry settings. Beginning her career at Dalton Pharma Services as a medicinal chemist, Harpreet has progressed into roles such as chemistry team leader, chemistry manager and associate director for R&D operations. Harpreet brings a broad range of drug development experience in preclinical, clinical, and commercial stages for more than 10 pre-clinical candidates and 2 commercial products. Her experience also includes contract research, process development and analytical method development and validation. She has served as SME for process development and analytical method development during FDA and Health Canada audits.

Harpreet completed her BSc degree in Biological Sciences, MSc and PhD degree in Organic Chemistry from Kurukshetra University, India.

Mohammad Eram

Mohammad Eram, PhD

Director Biology & Biophysics

Mohammad attained his PhD in Biochemistry and Enzymology at the University of Waterloo (Canada) and holds MSc degree in Medical Microbiology and a BSc degree in Cell and Molecular Biology. As the Director of Biology Department at Dalriada, he oversees the work of the cell biology, biochemistry and biophysics and proteomics teams.

Prior to joining Dalriada, Mohammad worked on early stage hit discovery projects at the Structural Genomics Consortium in Toronto, including projects in collaboration with Bayer, Takeda, Eli Lilly, and Merck. His work at SGC focused on biochemical and biophysical methods with applications to high-throughput and fragment-based drug discovery.

With over 17 years in biochemical/biophysical assays and small molecule R&D, Mohammad was involved in programs spanning small molecule inhibitor modalities including allosteric inhibitors, tight binders, targeted covalent therapeutics, and protein degraders. These programs covered a diverse range of protein targets including transcription factors, epigenetic modulators, oxidoreductases, dehydrogenases, kinases, methyl- and acetyltransferases, deacetylases, demethylases, PPI, GPCRs, and transcription regulators.

Jeff O’Meara

Jeff O’Meara, MSc

VP Drug Discovery

As Vice President, Drug Discovery at Dalriada, Jeff is responsible for overseeing all drug discovery activities from target identification to pre-clinical development. Jeff has nearly 30 years of drug discovery experience in hit ID, hit to lead, lead optimization and candidate nomination in projects targeting kinases, protein-protein interactions, protein degraders, covalent inhibitors, proteases and GPCRs in the areas of anti-infectives, oncology, immunomodulation, pain and CNS therapeutics. Prior to Dalriada, Jeff was Head of Research at M4K Pharma where he led a successful multinational open science lead optimization drug discovery project targeting DIPG, a rare childhood cancer.

Previously, Jeff spent 8 years as an integral part of the Ontario Institute for Cancer Research’s Drug Discovery team where he drove hit to lead and lead optimization projects of which two were eventually partnered with pharma in deals totaling > $2B. Jeff also trained for 17 years as a medicinal chemist and project team leader at Boehringer Ingelheim Canada Ltd. where he helped discover several novel antivirals that progressed to clinical trials. He has published more than 50 papers and patents in the fields of medicinal chemistry and drug discovery and in 2010 was the recipient of the American Chemical Society’s TAOC award.

Jeff has an M.Sc. in organic chemistry from University of Ottawa.

Tom Coulter

Tom Coulter, PhD

Head, Drug Discovery Programs and Partnerships

Tom is part of the R&D leadership team, overseeing partnership activities, drug discovery program planning and execution, as well as lifecycle management for current and prospective partners.

Over the past three decades, Tom has held senior roles in European pharma and biotech, including almost 20 years in contract research with Evotec as Senior Vice President, Drug Discovery, and more recently growing and leading Selvita’s integrated drug discovery portfolio.

Tom’s background is in medicinal chemistry, and he has extensive experience in the discovery and delivery of new small molecule and biologic agents targeting enzymes, GPCRs and other cell membrane targets including ion channels and SNARE proteins. He has managed multiple drug discovery programs covering the hit identification, hit to lead, and lead optimization stages of drug discovery, including 15 projects resulting in nomination of preclinical development candidates in the fields of cancer, inflammation, endocrine disease and antivirals. Tom has also contributed to the identification of multiple investigational new drugs. In recent years Tom has driven the identification of commercial opportunities as well as the creation and execution of sophisticated integrated discovery collaborations for clients.

Tom has a BSc (Hons) degree in chemistry from the Queen’s University of Belfast and a PhD in organic chemistry from the University of Leeds under Professor Ron Grigg. After completing his PhD, he joined Jim Thomas’ group at the University of Manchester before starting his industrial career at Organon.

Rav Kumar

Rav Kumar, PhD

Chief Strategy Officer

Dr. Rav Kumar is Chief Strategy Officer at Dalriada. He spent 25 years with GlaxoSmithKline (GSK) in the UK, France and Canada at vice-president level leading pharmaceutical R&D and business development. Key areas of expertise include formulation development, regulatory submissions, manufacturing and GMP audits. He has been involved with development of numerous medicines and vaccines plus many successful business change initiatives.

Most recently, he was Managing Director for Apotex in India (Bangalore and Mumbai), leading over 2,000 professionals in Pharmaceutical R&D, Manufacturing, Quality, Regulatory Affairs & Commercial Services.

Dr. Kumar is passionate about growing Canadian Life Sciences and has been involved with many industry-academic-government collaborations for which he was recognized with the Award for Leadership in in Canadian Pharmaceutical Sciences. He conceived the $150M spinout of GSK’s vaccines R&D to create the Neomed Vaccines and Biologics Centre of Excellence in Montreal. Other contributions include the CIHR Steering Committee for Patient Oriented Research, the Board of CQDM Research Consortium in Quebec and President of the Canadian Society for Pharmaceutical Sciences.

Dr. Kumar also serves as Director of The Centre for Medicinal Chemistry and an Assistant Professor at University of Toronto. He has a Pharmacy Degree and completed a PhD in Novel Drug Delivery at University of Bath in the UK.

Charlie Younger

Charlie Younger, PhD

Chief Operating Officer

Charlie joined Dalriada in 2020 as Chief Operating Officer, bringing over 25 years of pharma/biopharma experience. Charlie has a proven track record of leading organizations through rapid growth and transformations.

Charlie started his career as an Analytical Scientist at Glaxo and has taken on progressive leadership roles in pharma/biopharma. Charlie has worked with leading private and public pharma/biopharma organizations including leadership roles at CROs such as Patheon and Therapure Biopharma. He has also served as COO in both public and private organizations.

Driven by a personal passion to grow R&D in Canada, he has been a contributing member on multiple SR&ED tasks forces and executive roles in training organizations.

More recently, Charlie runs his own professional services business since 2016, helping companies grow and/or streamline operations for start-ups through to $B+ multinationals. He completed an HBSc in Chemistry at Western University (Canada) and a PhD in Organic Chemistry at McMaster University (Canada).

Patrick Gunning

Patrick Gunning, PhD

Co-founder & CSO

Patrick is a Professor of Chemistry at the University of Toronto, Canada Research Chair in Medicinal Chemistry, and Founder and Chief Scientific Director of the Centre for Medicinal Chemistry (UofT). Patrick obtained his PhD at the University of Glasgow in 2005 under the supervision of Profs. Robert Peacock and Andrew C. Benniston, and conducted post-doctoral studies at Yale University with Prof Andrew Hamilton.

Patrick’s research has focused on developing inhibitors of numerous protein classes, including transcription factors, kinases, and epigenetic targets, using novel covalent therapeutics and monovalent protein degraders. Patrick has published ~120 research papers, is a Fellow of the Royal Society of Chemistry, won 20 research awards including Canada’s Top 40 under 40, the 2010 Boehringer Ingelheim Young Investigator Award, the 2012 RSC MedChemComm Emerging Investigator Lectureship by the Royal Society for Chemistry, Rose Winer Levin Lectureship at the Dana-Farber Cancer Institute (2015), and the 2016 Canadian Society for Chemistry’s Bernard Belleau award.

Patrick, the co-founder and CSO of Dalriada Drug Discovery, has founded three other biotech companies with over $34M in funding, including Janpix Inc, now a Centessa Pharmaceuticals’ company, Dunad Therapeutics, and Dalriada Therapeutics.

Diana Kraskouskaya

Diana Kraskouskaya, PhD

Co-founder & CEO

Diana completed Honors BSc Degree in Molecular Biology and PhD in Medicinal Chemistry from the University of Toronto, and is a co-founder of two other biotechs, which have raised > $10 M in VC funding.

During her time in academia and biotech, Diana worked on diverse small molecule programs across protein-protein interactions, epigenetics, GPCRs, covalent inhibitors, and is an inventor on several patents.

As a co-founder and Chief Executive Officer of Dalriada, Diana brings to Dalriada years of leadership and hands-on cross-disciplinary biotech and drug discovery experience spanning areas of company building, scientific & IP program strategy, and operations. ​

Following completion of her PhD, Diana took appointment as a research manager of the Centre for Medicinal Chemistry, where she was involved in multiple drug discovery programs and provided oversight over the build-out of the >$100 M integrated drug discovery infrastructure at the University of Toronto. Diana co-founded and led two other biotechs, Dunad Therapeutics and Dalriada Therapeutics. In this process she recognized the shortcomings of the existing options for outsourcing innovative science, which led to the creation of Dalriada Drug Discovery’s Turn-Key™ Model. With this new model and under Diana’s leadership the company has grown to over 60 people within 3 years. ​

Diana is the recipient of several entrepreneurship awards, including RBC Prize for Innovation & Entrepreneurship and the 2018 MNP Future Leaders awards.

Get our latest news directly in your inbox!

We respect your inbox. No SPAM. Unsubscribe anytime.